Abstract
Breast cancer is a tumorous growth that develops in mammalian gland-lactating tissue's cell lines. Since aromatase controls how quickly estrogen is produced, it is crucial for treating estrogen-receptor positive breast cancer. The mainstay of treatment continues to be endocrine-based medications, which include aromatase inhibitors and estrogen receptor (ER) modifiers. Several synthetic aromatase inhibitors are now being used in clinical settings to treat hormone-receptor positive breast cancer in postmenopausal women. The hunt for novel aromatase inhibitors, particularly for those, whose activity is promoter-specific and further continues because these treatments could have undesirable side effects.
Abstract from the paper’s OpenAlex record; open copy licensed other-oa. Read at the source ↗
The text the model read, with the source record’s inline markup (italics, sub- and superscripts) rendered and its character entities decoded; quote offsets refer to the raw text.
Claims 0
Judged off_topic: human health or diet — claims were not extracted. This is a scope decision by the model, not a statement about the paper’s findings.